Effects of Ramipril on Plasma Fibrinolytic Balance in Patients With Acute Anterior Myocardial Infarction
- 15 July 1997
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 96 (2) , 442-447
- https://doi.org/10.1161/01.cir.96.2.442
Abstract
Background The long-term administration of ACE inhibitors to selected patients with left ventricular dysfunction appears to reduce the incidence of recurrent myocardial infarction (MI) and unstable angina pectoris. The mechanisms responsible for the reduction in ischemic events are unknown, but likely candidates include effects on the atherosclerotic process, thrombosis, and/or vascular tone. Methods and Results The effects of ACE inhibitor therapy with ramipril on plasma fibrinolytic variables were assessed in 120 subjects participating in the Healing and Early Afterload Reduction Therapy (HEART) study, a double-blind, placebo-controlled trial of acute anterior MI patients who were randomly assigned within 24 hours of the onset of symptoms to receive low-dose ramipril (0.625 mg daily), full-dose ramipril (1.25 mg titrated to 10 mg/d), or placebo for 14 days. Plasma levels of plasminogen activator inhibitor-1 (PAI-1) activity and PAI-1 antigen and tissue plasminogen activator (TPA) antigen were measured before randomization and on day 14. Clinical characteristics of the three study groups were similar, as were the prerandomization plasma levels of PAI-1 antigen, PAI-1 activity, and TPA antigen. Compared with the placebo group, PAI-1 antigen levels were 44% lower ( P =.004) at day 14 in the ramipril-treated patients, and PAI-1 activity levels were 22% lower ( P =.02). In contrast, plasma TPA levels were not significantly different between the placebo-treated and ramipril-treated groups. Conclusions Treatment with ramipril has a significant impact on plasma fibrinolytic variables during the recovery phase after acute MI. The renin-angiotensin system appears to play an important role in the regulation of vascular fibrinolysis, and interruption of this regulatory pathway may contribute to the clinical benefits of ACE inhibitors.Keywords
This publication has 28 references indexed in Scilit:
- Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibitionKidney International, 1997
- Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.Journal of Clinical Investigation, 1995
- Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarctionJournal of the American College of Cardiology, 1994
- Regulation of tissue-type plasminogen activator-mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischaemic heart diseaseCoronary Artery Disease, 1994
- Prospective study of endogenous tissue plasminogen activator and risk of strokeThe Lancet, 1994
- Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart StudyThe Lancet, 1993
- Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarctionNature, 1992
- Augmentation of plasminogen activator inhibitor type 1 activity in plasma by thrombosis and by thrombolysisJournal of the American College of Cardiology, 1991
- Association of the Renin-Sodium Profile with the Risk of Myocardial Infarction in Patients with HypertensionNew England Journal of Medicine, 1991
- Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial InfarctionNew England Journal of Medicine, 1985